Galectin Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: GALT · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1133416
| Field | Detail |
|---|---|
| Company | Galectin Therapeutics INC (GALT) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: GALT
TL;DR
GALECTIN THERAPEUTICS (GALT) filed an 8-K for shareholder vote matters on Jan 23rd.
AI Summary
Galectin Therapeutics Inc. filed an 8-K on January 28, 2025, reporting a submission of matters to a vote of security holders on January 23, 2025. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.
Why It Matters
This filing indicates that Galectin Therapeutics is engaging in corporate governance activities requiring shareholder input, which could impact the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding a shareholder vote, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- GALECTIN THERAPEUTICS INC (company) — Registrant
- PRO PHARMACEUTICALS INC (company) — Former company name
- January 23, 2025 (date) — Date of earliest event reported
- January 28, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- Norcross, GA (location) — Principal executive office location
FAQ
What specific matters were submitted for a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 23, 2025.
What is the current principal executive office address for Galectin Therapeutics Inc.?
The principal executive office is located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071.
What was Galectin Therapeutics Inc. formerly known as?
The company was formerly known as Pro Pharmaceuticals Inc.
In which state is Galectin Therapeutics Inc. incorporated?
Galectin Therapeutics Inc. is incorporated in Nevada.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 8.7 · Accepted 2025-01-28 08:00:14
Key Financial Figures
- $0.001 — ange on which registered Common Stock $0.001par value per share GALT The Nasdaq
Filing Documents
- ef20042347_8k.htm (8-K) — 46KB
- 0001140361-25-002125.txt ( ) — 181KB
- galt-20250123.xsd (EX-101.SCH) — 4KB
- galt-20250123_lab.xml (EX-101.LAB) — 21KB
- galt-20250123_pre.xml (EX-101.PRE) — 16KB
- ef20042347_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting of Stockholders held on January 23, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2024; The final results of the voting on each matter of business at the 2023 Annual Meeting are as follows: Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 18,236,198 1,013,767 20,045,381 Benjamin S. Carson, Sr., M.D. 18,935,118 314,847 20,045,381 Kary Eldred 18,919,225 330,740 20,045,381 Kevin D. Freeman 18,617,186 632,779 20,045,381 Joel Lewis 18,720,842 529,123 20,045,381 Gilbert S. Omenn, M.D., Ph.D. 19,000,733 249,232 20,045,381 Marc Rubin, M.D. 18,649,439 600,526 20,045,381 Elissa J. Schwartz, Ph.D. 18,980,465 269,500 20,045,381 Harold H. Shlevin, Ph.D. 18,719,597 530,368 20,045,381 Richard E. Uihlein, Chairman 18,988,589 261,376 20,045,381 Richard A. Zordani 18,993,681 256,284 20,045,381 Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2024 Votes For Votes Against Votes Abstain 38,723,588 162,839 408,919 - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: January 28, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -